Streamlined.financeStreamlined.finance
MarketsFind Stocks

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

DexCom, Inc.

NASDAQ

Market Cap.

25.45B

Avg. Volume

2.74M

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about DexCom, Inc.

DexCom, Inc. News

DexCom, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareMedical - Devices
dexcom.com

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc. Earnings & Revenue

DexCom, Inc. Financials

Table Compare

Compare DXCM metrics with:

   

Earnings & Growth

DXCM

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

DXCM

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

DXCM

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

DXCM

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

DexCom, Inc. Income

DexCom, Inc. Balance Sheet

DexCom, Inc. Cash Flow

DexCom, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

DexCom, Inc. Executives

NameRole
Mr. Kevin Ronald SayerExecutive Chairman, Chief Executive Officer & President
Ms. Teri LawverExecutive Vice President & Chief Commercial Officer
Mr. Jacob Steven LeachExecutive Vice President & Chief Operating Officer
Mr. Michael Jon BrownExecutive Vice President & Chief Legal Officer
Mr. Jereme M. SylvainExecutive Vice President, Chief Financial Officer & Chief Accounting Officer
NameRoleGenderDate of BirthPay
Mr. Kevin Ronald SayerExecutive Chairman, Chief Executive Officer & PresidentMale19583.23M
Ms. Teri LawverExecutive Vice President & Chief Commercial OfficerFemale19671.41M
Mr. Jacob Steven LeachExecutive Vice President & Chief Operating OfficerMale19781.29M
Mr. Michael Jon BrownExecutive Vice President & Chief Legal OfficerMale19701.22M
Mr. Jereme M. SylvainExecutive Vice President, Chief Financial Officer & Chief Accounting OfficerMale19801.13M

DexCom, Inc. Insider Trades

Date28 Jun
NameBrown Michael Jon
RoleEVP Chief Legal Officer
TransactionDisposed
TypeS-Sale
Shares659
Date17 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares7
Date17 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares2212
Date17 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares475
Date18 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares3007
DateNameRoleTransactionTypeShares
28 JunBrown Michael JonEVP Chief Legal OfficerDisposedS-Sale659
17 JunFOLETTA MARK GDirectorDisposedS-Sale7
17 JunFOLETTA MARK GDirectorDisposedS-Sale2212
17 JunFOLETTA MARK GDirectorDisposedS-Sale475
18 JunFOLETTA MARK GDirectorDisposedS-Sale3007

Discover More

Streamlined Academy

DexCom, Inc.

NASDAQ

Market Cap.

25.45B

Avg. Volume

2.74M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

DexCom, Inc. News

DexCom, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

DexCom, Inc. Earnings & Revenue

DexCom, Inc. Income

DexCom, Inc. Balance Sheet

DexCom, Inc. Cash Flow

DexCom, Inc. Financials Over Time

DexCom, Inc. Executives

NameRole
Mr. Kevin Ronald SayerExecutive Chairman, Chief Executive Officer & President
Ms. Teri LawverExecutive Vice President & Chief Commercial Officer
Mr. Jacob Steven LeachExecutive Vice President & Chief Operating Officer
Mr. Michael Jon BrownExecutive Vice President & Chief Legal Officer
Mr. Jereme M. SylvainExecutive Vice President, Chief Financial Officer & Chief Accounting Officer
NameRoleGenderDate of BirthPay
Mr. Kevin Ronald SayerExecutive Chairman, Chief Executive Officer & PresidentMale19583.23M
Ms. Teri LawverExecutive Vice President & Chief Commercial OfficerFemale19671.41M
Mr. Jacob Steven LeachExecutive Vice President & Chief Operating OfficerMale19781.29M
Mr. Michael Jon BrownExecutive Vice President & Chief Legal OfficerMale19701.22M
Mr. Jereme M. SylvainExecutive Vice President, Chief Financial Officer & Chief Accounting OfficerMale19801.13M

DexCom, Inc. Insider Trades

Date28 Jun
NameBrown Michael Jon
RoleEVP Chief Legal Officer
TransactionDisposed
TypeS-Sale
Shares659
Date17 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares7
Date17 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares2212
Date17 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares475
Date18 Jun
NameFOLETTA MARK G
RoleDirector
TransactionDisposed
TypeS-Sale
Shares3007
DateNameRoleTransactionTypeShares
28 JunBrown Michael JonEVP Chief Legal OfficerDisposedS-Sale659
17 JunFOLETTA MARK GDirectorDisposedS-Sale7
17 JunFOLETTA MARK GDirectorDisposedS-Sale2212
17 JunFOLETTA MARK GDirectorDisposedS-Sale475
18 JunFOLETTA MARK GDirectorDisposedS-Sale3007

Streamlined Academy

Website screenshot
HealthcareMedical - Devices
dexcom.com

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about DexCom, Inc.

DexCom, Inc. Financials

Table Compare

Compare DXCM metrics with:

   

Earnings & Growth

DXCM

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

DXCM

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

DXCM

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

DXCM

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

DexCom, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More